Qualitative and quantitative composition:
One gram of gel contains 3.3 mg of brimonidine, equivalent to 5 mg of brimonidine tartrate.
Excipient(s) with known effect:
One gram of gel contains 1 mg methylparahydroxybenzoate (E218) and 55 mg propylene glycol (E1520).
Therapeutic indications:
Mirvaso is indicated for the symptomatic treatment of facial erythema of rosacea in adult patients.
